Media headlines about AbbVie (NYSE:ABBV) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AbbVie earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.4319396047114 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Focus on Unusual Volume Mover: AbbVie Inc. (ABBV) – Wall Street Morning (wallstreetmorning.com)
- Zacks Investment Research Downgrades AbbVie (ABBV) to Hold (americanbankingnews.com)
- Obsessive-Compulsive Disorder – Pipeline Review, H2 2017 increasing demand with key players: AbbVie Inc, Addex … – Healthcare Journal (journalhealthcare.com)
- AbbVie Inc. (ABBV) : Investors may need a consensus Analysts Rating – Wall Street Morning (wallstreetmorning.com)
- BRIEF-AbbVie Says CEO’s 2017 Total Compensations Were $22.63 Mln Vs $20.97 Mln In 2016 – Reuters (reuters.com)
Shares of AbbVie (NYSE ABBV) traded up $0.62 during mid-day trading on Tuesday, reaching $112.65. 4,933,785 shares of the company traded hands, compared to its average volume of 6,710,733. AbbVie has a one year low of $63.12 and a one year high of $125.86. The stock has a market cap of $180,568.41, a P/E ratio of 34.24, a price-to-earnings-growth ratio of 1.07 and a beta of 1.52. The company has a quick ratio of 1.18, a current ratio of 1.28 and a debt-to-equity ratio of 6.07.
AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, January 26th. The company reported $1.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.44 by $0.04. AbbVie had a net margin of 18.82% and a return on equity of 158.15%. The company had revenue of $7.74 billion for the quarter, compared to the consensus estimate of $7.53 billion. During the same period in the prior year, the firm posted $1.20 EPS. AbbVie’s revenue for the quarter was up 13.9% on a year-over-year basis. analysts anticipate that AbbVie will post 7.48 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 15th. Investors of record on Friday, April 13th will be given a dividend of $0.96 per share. This represents a $3.84 annualized dividend and a yield of 3.41%. This is an increase from AbbVie’s previous quarterly dividend of $0.71. The ex-dividend date is Thursday, April 12th. AbbVie’s dividend payout ratio is 86.32%.
AbbVie announced that its Board of Directors has approved a stock buyback plan on Thursday, February 15th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company’s board believes its stock is undervalued.
A number of brokerages have issued reports on ABBV. Piper Jaffray Companies boosted their price objective on shares of AbbVie from $115.00 to $130.00 and gave the company an “outperform” rating in a research report on Friday, January 26th. SunTrust Banks upped their target price on shares of AbbVie to $157.00 and gave the stock an “average” rating in a research report on Monday, January 29th. Leerink Swann downgraded shares of AbbVie from an “outperform” rating to a “market perform” rating and set a $127.00 target price on the stock. in a research report on Monday, January 29th. BMO Capital Markets downgraded shares of AbbVie from a “market perform” rating to an “underperform” rating and reduced their target price for the stock from $125.86 to $84.00 in a research report on Monday, January 29th. They noted that the move was a valuation call. Finally, Evercore ISI reaffirmed a “buy” rating and issued a $144.00 target price on shares of AbbVie in a research report on Monday, January 29th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $120.96.
In other AbbVie news, EVP Carlos Alban sold 83,574 shares of the company’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $114.49, for a total transaction of $9,568,387.26. Following the transaction, the executive vice president now owns 133,026 shares in the company, valued at approximately $15,230,146.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert A. Michael sold 992 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $120.31, for a total transaction of $119,347.52. The disclosure for this sale can be found here. Insiders have sold a total of 211,197 shares of company stock worth $24,585,575 over the last three months. 0.23% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact AbbVie (ABBV) Stock Price” was published by Stock Observer and is owned by of Stock Observer. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.thestockobserver.com/2018/03/20/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-abbvie-abbv-stock-price.html.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.